Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Metrics to compare | PHVS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHVSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.1x | −10.0x | −0.5x | |
PEG Ratio | 0.47 | 0.21 | 0.00 | |
Price/Book | 5.9x | 4.5x | 2.6x | |
Price / LTM Sales | - | 384.0x | 3.2x | |
Upside (Analyst Target) | 49.0% | 110.4% | 47.4% | |
Fair Value Upside | Unlock | −3.0% | 7.7% | Unlock |